Table 1.
Summary of pending focal therapy trials.
| Modality | Protocol | n | Biopsy | PSA | GS | |
|---|---|---|---|---|---|---|
| MSKCC | Cryotherapy | Hemiablation | 50 | TRUS | <10 | ≤6 |
| MD Anderson | Cryotherapy | Extended | 100 | TRUS | <10 | <3+4 |
| hemiablation | ||||||
| Milan, Italy | Cryotherapy | Hemiablation | 100 | TRUS | <10 | ≤6 |
| Ahmed/Emberton | HIFU | Focal | 43 | Template | <15 | ≤7 |
| Ahmed/Emberton | H1FU | Index lesion | 26 | Template or | <15 | ≤8 |
| TRUS/MRI | ||||||
| France | HIFU | Hemiablation | 120 | TRUS/MRI | <10 | ≤7 |
| Multicenter | HIFU | Focal, Hemiablation, | 150 | Template or | <15 | ≤7 |
| Europe | Index lesion | TRUS/MRI | ||||
| Multicenter | PDT-WST-11 | Variable | 85 | Not reported | Not | Not |
| Europe | reported | reported |
PSA, prostate-specific antigen; GS, Gleason Score; HIFU, high-frequency ultrasound; TRUS, transrectal ultrasound; MRI, magnetic resonance imaging; PDT, photodynamic therapy.